Search results for "Rating scale"

showing 10 items of 537 documents

Estimation of the dimensionality of sleep-EEG data in schizophrenics

1993

Deterministic chaos could be regarded as a healthy flexibility of the human brain necessary for correct neuronal operations. Several investigations have demonstrated that in healthy subjects the dimensionality of REM sleep is much higher than that of slow wave sleep (SWS). We investigated the sleep-EEG of schizophrenic patients with methods from nonlinear system theory in order to estimate the dynamic properties of CNS. We hypothesized that schizophrenics would reveal alterations of their dynamic EEG features indicating impaired information processing. In 11 schizophrenic patients, the EEG's dimensionality during sleep stages II and REM was reduced. We suggest that such lower dimensional ch…

AdultMalePsychosisPolysomnographymedia_common.quotation_subjectRapid eye movement sleepSleep REMElectroencephalographyMental ProcessesReaction TimemedicineHumansPharmacology (medical)Biological PsychiatrySlow-wave sleepmedia_commonCerebral CortexPsychiatric Status Rating ScalesSleep Stagesmedicine.diagnostic_testSignal Processing Computer-AssistedGeneral MedicineHuman brainmedicine.diseasePsychiatry and Mental healthmedicine.anatomical_structureSchizophreniaFemaleSchizophrenic PsychologyNerve NetPsychologyNeurosciencePsychopathologyVigilance (psychology)European Archives of Psychiatry and Clinical Neuroscience
researchProduct

Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFI…

2013

Abstract Objective Predicting response to antipsychotic treatment might optimize treatment strategies in early phases of schizophrenia. We aimed to investigate sociodemographic, premorbid and clinical predictors of response to antipsychotic treatment after a first episode of non-affective psychosis. Method 375 (216 males) patients with a diagnosis of non affective psychosis entered the study. The main outcome measure was clinical response at 6 weeks and variables at baseline were evaluated as predictors of response. ANOVA for continuous and chi-square for categorical data were used to compare responders and non-responders. Multivariate logistic regression was used to establish a prediction …

AdultMalePsychosismedicine.medical_specialtyAdolescentLogistic regressionCohort StudiesYoung AdultPredictive Value of TestsOutcome Assessment Health CaremedicineHumansFamily historyPsychiatryBiological PsychiatryRetrospective StudiesPharmacologyFirst episodePsychiatric Status Rating ScalesAnalysis of VarianceChi-Square DistributionMiddle Agedmedicine.diseaseLogistic ModelsPsychotic DisordersSchizophreniaSpainCohortdupFemalePsychologyDiagnosis of schizophreniaAntipsychotic AgentsProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Correlates of Symptom Dimensions in Schizophrenia Obtained with the Spanish Version of the Manchester Scale

2000

In the last decade, a significant number of studies have been published which suggest a multifactorial psychopathological structure in schizophrenia. Seventy-eight acute and chronic schizophrenic patients diagnosed in accordance with DSM-III-R criteria were studied with the Manchester Scale, Premorbid Adjustment Scale, Family History-RDC Interview, Digit Span, Mini-Mental State and computerized tomography (CT). A factorial analysis of the symptoms as recorded with the Spanish version of the Manchester Scale was carried out. Three factors (‘positive’, ‘negative’ and ‘disorganization’) accounted for 79% of the total variance. Poor premorbid adjustment was associated with high scores for the ‘…

AdultMalePsychosismedicine.medical_specialtyAdolescentPsychometricsPsychometricsTest validitySeverity of Illness Indexmental disordersSeverity of illnessmedicineMemory spanHumansPsychiatryLanguagePsychiatric Status Rating ScalesBrainMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologySchizophreniaScale (social sciences)SchizophreniaFemaleFactor Analysis StatisticalTomography X-Ray ComputedPsychologyPsychopathologyPsychopathology
researchProduct

Three dimensions of depression in patients with acute psychotic disorders: A replication study

1999

Depressive symptoms in psychotic disorders are of high relevance but seem to be heterogeneous when assessed with a standard rating scale. The present analysis is a replication study on the dimensionality of the Bech-Rafaelsen Melancholia Scale (BRMES) in acutely psychotic patients with substantial depression defined according to a functional approach across the nosological borders of schizophrenia with major affective symptoms, schizoaffective disorder, depressed subtype, and major depression with psychotic features. The baseline data of 123 patients participating in a multicenter pharmacological trial were evaluated with structural equation models. A previously reported three-dimensional m…

AdultMalePsychosismedicine.medical_specialtyAdolescentPsychometricslcsh:RC435-571Schizoaffective disorderSeverity of Illness IndexStructural equation modelingRating scalelcsh:PsychiatryMelancholiamedicineHumansPsychiatryAgedPsychiatric Status Rating ScalesDepressive Disorder MajorReproducibility of ResultsMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologyPsychotic DisordersSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychomotor Disordersmedicine.symptomFactor Analysis StatisticalPsychologyPsychomotor disorderClinical psychologyComprehensive Psychiatry
researchProduct

Suicidal behaviour in first-episode non-affective psychosis: Specific risk periods and stage-related factors

2014

Suicide is a major cause of premature death in psychosis. Earlier stages have been associated with higher risk. However, such risk periods have not been specifically determined and risk factors for suicidal behaviour may change over those periods, which may have crucial implications for suicide prevention. The aim of this study was to determine and characterize the highest risk period for suicide in a representative sample of first-episode psychosis (FEP) patients. Suicidal behaviour prior to first presentation of psychosis and during a 3-year follow-up was examined in a sample of 397 individuals. Risk factors for suicidal behaviour during specific time periods were investigated and compare…

AdultMalePsychosismedicine.medical_specialtyAdolescentSpecific riskPoison controlNeuropsychological TestsSuicide preventionYoung AdultCognitionmedicineHumansPharmacology (medical)PsychiatryBiological PsychiatryPsychiatric Status Rating ScalesPharmacologyFirst episodeSuicide attemptMiddle Agedmedicine.diseaseSurvival AnalysisSuicidePsychiatry and Mental healthPsychotic DisordersNeurologySchizophreniaRegression AnalysisAnxietyFemaleNeurology (clinical)medicine.symptomPsychologySelf-Injurious BehaviorClinical psychologyEuropean Neuropsychopharmacology
researchProduct

Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic bipolar and healthy subjects.

2007

Objective:  Only a few studies have examined specifically the neuropsychological performance of schizoaffective patients. Method:  The sample consisted of 34 euthymic DSM-IV schizoaffective patients, who were compared with 41 euthymic bipolar patients without history of psychotic symptoms and 35 healthy controls. Euthymia was defined by a score of 6 or less at the Young Mania Rating Scale and a score of 8 or less at the Hamilton Depression Rating Scale for at least 6 months. Patients were compared with several clinical, occupational, and neuropsychological variables such as executive function, attention, verbal and visual memory and the two groups were contrasted with 35 healthy controls on…

AdultMalePsychosismedicine.medical_specialtyBipolar DisorderHealth StatusSchizoaffective disorderNeuropsychological TestsYoung Mania Rating ScaleSeverity of Illness IndexSurveys and QuestionnairesmedicineVerbal fluency testHumansBipolar disorderPsychiatryDemographyCognitive disorderBrainmedicine.diseasePsychiatry and Mental healthCross-Sectional StudiesPsychotic DisordersFemaleVerbal memoryPsychologyCognition DisordersNeurocognitiveClinical psychologyActa psychiatrica Scandinavica
researchProduct

Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S)

2009

To demonstrate the ability of the Screen for Cognitive Impairment in Psychiatry (SCIP-S) to discriminate between cognitively-impaired individuals and those with adequate functioning in a sample of schizophrenic and bipolar patients, as well as in a control group.The SCIP-S, together with a full neuropsychological battery, was administered to three groups: patients with schizophrenia, patients diagnosed with bipolar disorder I, and controls. The battery scores were used to perform a standardization with respect to the control group and this served to determine the comparison groups (cognitively impaired versus unimpaired) for each of the subtests of the SCIP-S. A full analysis of decision va…

AdultMalePsychosismedicine.medical_specialtyBipolar DisorderNeuropsychological TestsSeverity of Illness Indexmental disordersmedicineHumansBipolar disorderPsychiatryBiological PsychiatryCognitive deficitPsychiatric Status Rating ScalesReceiver operating characteristicCognitive disorderCognitionMiddle Agedmedicine.diseasePsychiatry and Mental healthROC CurveSchizophreniaSchizophreniaFemalemedicine.symptomCognition DisordersPsychologyNeurocognitiveClinical psychologySchizophrenia Research
researchProduct

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and cha…

1995

Preclinical data indicated that seroquel (ICI 204 636), a dibenzothiazepine with 5-HT2 and D2-like receptor antagonistic properties, might be an effective antipsychotic agent, causing fewer extrapyramidal side effects than typical neuroleptics. In the present study, 12 patients suffering from schizophrenia or schizophreniform disorder with predominantly positive symptomatology were treated in an open clinical trial for 4 weeks with seroquel at a maximum dosage of 750 mg/day. The drug was generally well tolerated, and virtually no adverse extrapyramidal side effects such as acute dystonia, parkinsonism or akathisia were observed. Total scores for BPRS (item score 0–6; baseline: 42.0±2.3; mea…

AdultMalePsychosismedicine.medical_specialtyDibenzothiazepinesTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticThyrotropinAkathisiaGastroenterologyQuetiapine FumarateAntipsychotic AgentInternal medicinemedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesParkinsonismElectroencephalographyMiddle Agedmedicine.diseaseProlactinTreatment OutcomeSchizophreniaAnesthesiaSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologyAntipsychotic AgentsPsychopharmacology
researchProduct

Differences in cannabis-related experiences between patients with a first episode of psychosis and controls

2016

BackgroundMany studies have reported that cannabis use increases the risk of a first episode of psychosis (FEP). However, only a few studies have investigated the nature of cannabis-related experiences in FEP patients, and none has examined whether these experiences are similar in FEP and general populations. The aim of this study was to explore differences in self-reported cannabis experiences between FEP and non-psychotic populations.MethodA total of 252 subjects, who met International Classification of Diseases (ICD)-10 criteria for FEP, and 217 controls who reported cannabis use were selected from the Genetics and Psychosis (GAP) study. The Medical Research Council Social Schedule and t…

AdultMalePsychosismedicine.medical_specialtyExacerbationPopulationMarijuana SmokingSociodemographic datapsychosiPsychotic Disorder03 medical and health sciencesYoung Adult0302 clinical medicineexperienceSurveys and QuestionnairesmedicineSettore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat.HumansSurveys and QuestionnaireCannabiYoung adulteducationPsychiatrySettore MED/25 - PsichiatriaApplied PsychologyCannabisCannabis; Cannabis Experience Questionnaire; experiences; first episode of psychosis; psychosis; Adult; Cannabis; Female; Humans; Linear Models; Male; Marijuana Smoking; Psychiatric Status Rating Scales; Psychotic Disorders; Surveys and Questionnaires; Young Adult; Applied Psychology; Psychiatry and Mental Healthfirst episode of psychosiFirst episodePsychiatric Status Rating Scaleseducation.field_of_studybiologyCannabis usePsychiatric Status Rating Scalemedicine.diseasebiology.organism_classification030227 psychiatryPsychotic DisordersPsychiatry and Mental HealthCannabis Experience QuestionnaireLinear ModelsLinear ModelFemaleCannabisPsychology030217 neurology & neurosurgeryClinical psychologyHuman
researchProduct

Spectroscopic metabolomic abnormalities in the thalamus related to auditory hallucinations in patients with schizophrenia

2008

Abstract Objective Previous studies have found neurochemical abnormalities in thalamic nuclei in patients with schizophrenia. These abnormalities have been associated with information processing deficiencies and symptom formation. There are no metabolic spectroscopy studies in patients with schizophrenia attending to auditory hallucinations. The aim of the present study is to explore metabolic Magnetic Resonance Spectroscopy (MRS) ratio differences in the thalamus between schizophrenic patients with and without auditory hallucinations and control subjects. Methods MRS studies (MRI 1.5 T unit) were performed in 49 patients with schizophrenia (30 with auditory hallucinations and 19 without au…

AdultMalePsychosismedicine.medical_specialtyMagnetic Resonance SpectroscopyHallucinationsThalamusAudiologyFunctional LateralityCholineThalamusBrief Psychiatric Rating ScalemedicineBrief Psychiatric Rating ScaleHumansBiological PsychiatryAspartic AcidAuditory hallucinationmedicine.diagnostic_testPositive and Negative Syndrome ScaleMagnetic resonance imagingCreatinemedicine.diseaseDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthSchizophreniaSchizophreniaAge of onsetmedicine.symptomPsychologyNeuroscienceSchizophrenia Research
researchProduct